Drugs / rDEN4delta30-200,201
last change Dec 2009 re-read 3 minutes ago

rDEN4delta30-200,201

Vaccine

Developed for
dengue disease
Investigated by
Johns Hopkins Bloomberg School of Public Health · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00270699 Jun 2006 → Dec 2009 dengue disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as rDEN4delta30-200,201 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00270699 ↗
Modality Vaccine “live attenuated dengue virus vaccine” NCT00270699 ↗
Route Subcutaneous “One subcutaneous vaccination with rDEN4delta30-200,201 vaccine” NCT00270699 ↗